nodes	percent_of_prediction	percent_of_DWPC	metapath
Flunitrazepam—UGT2B7—Mycophenolic acid—psoriasis	0.14	0.166	CbGbCtD
Flunitrazepam—UGT1A1—Mycophenolic acid—psoriasis	0.121	0.143	CbGbCtD
Flunitrazepam—UGT2B7—Mycophenolate mofetil—psoriasis	0.0785	0.0926	CbGbCtD
Flunitrazepam—CYP2A6—Methoxsalen—psoriasis	0.0702	0.0828	CbGbCtD
Flunitrazepam—UGT1A1—Mycophenolate mofetil—psoriasis	0.0678	0.08	CbGbCtD
Flunitrazepam—CYP1A2—Clobetasol propionate—psoriasis	0.051	0.0601	CbGbCtD
Flunitrazepam—CYP2A6—Prednisolone—psoriasis	0.0341	0.0402	CbGbCtD
Flunitrazepam—CYP2B6—Cholecalciferol—psoriasis	0.0303	0.0357	CbGbCtD
Flunitrazepam—CYP1A2—Methoxsalen—psoriasis	0.0268	0.0316	CbGbCtD
Flunitrazepam—CYP2A6—Dexamethasone—psoriasis	0.0201	0.0237	CbGbCtD
Flunitrazepam—CYP2C19—Cholecalciferol—psoriasis	0.0192	0.0227	CbGbCtD
Flunitrazepam—CYP3A4—Calcitriol—psoriasis	0.018	0.0213	CbGbCtD
Flunitrazepam—CYP2C9—Cholecalciferol—psoriasis	0.016	0.0189	CbGbCtD
Flunitrazepam—CYP3A4—Methoxsalen—psoriasis	0.014	0.0165	CbGbCtD
Flunitrazepam—CYP2C19—Prednisone—psoriasis	0.0133	0.0157	CbGbCtD
Flunitrazepam—CYP2E1—Dexamethasone—psoriasis	0.0133	0.0157	CbGbCtD
Flunitrazepam—CYP2B6—Dexamethasone—psoriasis	0.0131	0.0154	CbGbCtD
Flunitrazepam—CYP2C19—Cyclosporine—psoriasis	0.0126	0.0149	CbGbCtD
Flunitrazepam—CYP2C9—Cyclosporine—psoriasis	0.0105	0.0124	CbGbCtD
Flunitrazepam—CYP3A4—Cholecalciferol—psoriasis	0.0093	0.011	CbGbCtD
Flunitrazepam—CYP2C19—Dexamethasone—psoriasis	0.00832	0.00981	CbGbCtD
Flunitrazepam—CYP3A4—Mycophenolate mofetil—psoriasis	0.00806	0.00951	CbGbCtD
Flunitrazepam—CYP3A4—Triamcinolone—psoriasis	0.00806	0.00951	CbGbCtD
Flunitrazepam—CYP2C9—Dexamethasone—psoriasis	0.00692	0.00816	CbGbCtD
Flunitrazepam—CYP3A4—Betamethasone—psoriasis	0.00692	0.00816	CbGbCtD
Flunitrazepam—CYP3A4—Prednisolone—psoriasis	0.00682	0.00805	CbGbCtD
Flunitrazepam—CYP3A4—Hydrocortisone—psoriasis	0.00647	0.00763	CbGbCtD
Flunitrazepam—CYP3A4—Prednisone—psoriasis	0.00644	0.0076	CbGbCtD
Flunitrazepam—CYP3A4—Cyclosporine—psoriasis	0.00611	0.0072	CbGbCtD
Flunitrazepam—CYP3A4—Dexamethasone—psoriasis	0.00402	0.00474	CbGbCtD
Flunitrazepam—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.00194	0.0592	CbGpPWpGaD
Flunitrazepam—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00156	0.0478	CbGpPWpGaD
Flunitrazepam—CYP2E1—CYP2E1 reactions—CYP2S1—psoriasis	0.00153	0.0468	CbGpPWpGaD
Flunitrazepam—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.0012	0.0367	CbGpPWpGaD
Flunitrazepam—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00118	0.0361	CbGpPWpGaD
Flunitrazepam—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00108	0.0329	CbGpPWpGaD
Flunitrazepam—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.00097	0.0296	CbGpPWpGaD
Flunitrazepam—CYP2E1—Xenobiotics—CYP2S1—psoriasis	0.00095	0.029	CbGpPWpGaD
Flunitrazepam—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000733	0.0224	CbGpPWpGaD
Flunitrazepam—Disorientation—Cyclosporine—psoriasis	0.000692	0.0058	CcSEcCtD
Flunitrazepam—Muscular weakness—Mycophenolic acid—psoriasis	0.000674	0.00566	CcSEcCtD
Flunitrazepam—Hypotension—Methoxsalen—psoriasis	0.000674	0.00565	CcSEcCtD
Flunitrazepam—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000668	0.0204	CbGpPWpGaD
Flunitrazepam—Anxiety—Calcitriol—psoriasis	0.000668	0.00561	CcSEcCtD
Flunitrazepam—Discomfort—Calcitriol—psoriasis	0.000662	0.00556	CcSEcCtD
Flunitrazepam—Dry mouth—Calcitriol—psoriasis	0.000656	0.0055	CcSEcCtD
Flunitrazepam—Ill-defined disorder—Acitretin—psoriasis	0.00065	0.00545	CcSEcCtD
Flunitrazepam—Hiccups—Dexamethasone—psoriasis	0.000647	0.00543	CcSEcCtD
Flunitrazepam—Hiccups—Betamethasone—psoriasis	0.000647	0.00543	CcSEcCtD
Flunitrazepam—Amnesia—Mycophenolate mofetil—psoriasis	0.000642	0.00539	CcSEcCtD
Flunitrazepam—Angioedema—Acitretin—psoriasis	0.00064	0.00537	CcSEcCtD
Flunitrazepam—Rash—Clobetasol propionate—psoriasis	0.000638	0.00536	CcSEcCtD
Flunitrazepam—Dermatitis—Clobetasol propionate—psoriasis	0.000638	0.00535	CcSEcCtD
Flunitrazepam—Headache—Clobetasol propionate—psoriasis	0.000634	0.00532	CcSEcCtD
Flunitrazepam—Malaise—Acitretin—psoriasis	0.000632	0.0053	CcSEcCtD
Flunitrazepam—Hallucination—Hydroxyurea—psoriasis	0.000628	0.00528	CcSEcCtD
Flunitrazepam—Dizziness—Beclomethasone—psoriasis	0.00061	0.00512	CcSEcCtD
Flunitrazepam—Dizziness—Fluocinonide—psoriasis	0.000604	0.00507	CcSEcCtD
Flunitrazepam—Diplopia—Mycophenolate mofetil—psoriasis	0.000604	0.00507	CcSEcCtD
Flunitrazepam—Anxiety—Acitretin—psoriasis	0.000594	0.00499	CcSEcCtD
Flunitrazepam—Feeling abnormal—Methoxsalen—psoriasis	0.000594	0.00499	CcSEcCtD
Flunitrazepam—Psychotic disorder—Mycophenolate mofetil—psoriasis	0.000589	0.00495	CcSEcCtD
Flunitrazepam—Discomfort—Acitretin—psoriasis	0.000589	0.00494	CcSEcCtD
Flunitrazepam—Dry mouth—Acitretin—psoriasis	0.000583	0.00489	CcSEcCtD
Flunitrazepam—Rash—Beclomethasone—psoriasis	0.000581	0.00488	CcSEcCtD
Flunitrazepam—Dermatitis—Beclomethasone—psoriasis	0.000581	0.00487	CcSEcCtD
Flunitrazepam—Headache—Beclomethasone—psoriasis	0.000577	0.00485	CcSEcCtD
Flunitrazepam—Rash—Fluocinonide—psoriasis	0.000576	0.00483	CcSEcCtD
Flunitrazepam—Dermatitis—Fluocinonide—psoriasis	0.000575	0.00483	CcSEcCtD
Flunitrazepam—Headache—Fluocinonide—psoriasis	0.000572	0.0048	CcSEcCtD
Flunitrazepam—Somnolence—Calcitriol—psoriasis	0.000571	0.00479	CcSEcCtD
Flunitrazepam—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000571	0.0174	CbGpPWpGaD
Flunitrazepam—Sweating—Mycophenolic acid—psoriasis	0.000565	0.00474	CcSEcCtD
Flunitrazepam—Hiccups—Prednisone—psoriasis	0.000564	0.00473	CcSEcCtD
Flunitrazepam—Hyperhidrosis—Acitretin—psoriasis	0.000553	0.00464	CcSEcCtD
Flunitrazepam—Orthostatic hypotension—Mycophenolate mofetil—psoriasis	0.000551	0.00463	CcSEcCtD
Flunitrazepam—Muscular weakness—Cyclosporine—psoriasis	0.000546	0.00458	CcSEcCtD
Flunitrazepam—Psychotic disorder—Hydrocortisone—psoriasis	0.000537	0.00451	CcSEcCtD
Flunitrazepam—Muscular weakness—Mycophenolate mofetil—psoriasis	0.000532	0.00447	CcSEcCtD
Flunitrazepam—Hallucination—Mycophenolic acid—psoriasis	0.000526	0.00442	CcSEcCtD
Flunitrazepam—Irritability—Hydrocortisone—psoriasis	0.000525	0.0044	CcSEcCtD
Flunitrazepam—Ill-defined disorder—Hydroxyurea—psoriasis	0.00051	0.00428	CcSEcCtD
Flunitrazepam—Somnolence—Acitretin—psoriasis	0.000508	0.00427	CcSEcCtD
Flunitrazepam—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000499	0.0152	CbGpPWpGaD
Flunitrazepam—Dysarthria—Methotrexate—psoriasis	0.000498	0.00418	CcSEcCtD
Flunitrazepam—Muscular weakness—Prednisolone—psoriasis	0.000497	0.00417	CcSEcCtD
Flunitrazepam—Malaise—Hydroxyurea—psoriasis	0.000496	0.00416	CcSEcCtD
Flunitrazepam—Fatigue—Acitretin—psoriasis	0.000493	0.00414	CcSEcCtD
Flunitrazepam—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000493	0.015	CbGpPWpGaD
Flunitrazepam—Muscular weakness—Hydrocortisone—psoriasis	0.000485	0.00407	CcSEcCtD
Flunitrazepam—Dizziness—Methoxsalen—psoriasis	0.000477	0.004	CcSEcCtD
Flunitrazepam—Feeling abnormal—Acitretin—psoriasis	0.000471	0.00395	CcSEcCtD
Flunitrazepam—Discomfort—Hydroxyurea—psoriasis	0.000463	0.00388	CcSEcCtD
Flunitrazepam—Asthenia—Calcitriol—psoriasis	0.000461	0.00387	CcSEcCtD
Flunitrazepam—Psychotic disorder—Betamethasone—psoriasis	0.000459	0.00385	CcSEcCtD
Flunitrazepam—Psychotic disorder—Dexamethasone—psoriasis	0.000459	0.00385	CcSEcCtD
Flunitrazepam—Muscular weakness—Triamcinolone—psoriasis	0.000457	0.00383	CcSEcCtD
Flunitrazepam—Rash—Methoxsalen—psoriasis	0.000455	0.00382	CcSEcCtD
Flunitrazepam—Dermatitis—Methoxsalen—psoriasis	0.000454	0.00381	CcSEcCtD
Flunitrazepam—Headache—Methoxsalen—psoriasis	0.000452	0.00379	CcSEcCtD
Flunitrazepam—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.00045	0.0137	CbGpPWpGaD
Flunitrazepam—Irritability—Dexamethasone—psoriasis	0.000448	0.00376	CcSEcCtD
Flunitrazepam—Irritability—Betamethasone—psoriasis	0.000448	0.00376	CcSEcCtD
Flunitrazepam—Sweating—Mycophenolate mofetil—psoriasis	0.000446	0.00374	CcSEcCtD
Flunitrazepam—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000441	0.0135	CbGpPWpGaD
Flunitrazepam—Amnesia—Prednisone—psoriasis	0.000435	0.00365	CcSEcCtD
Flunitrazepam—Tremor—Mycophenolic acid—psoriasis	0.000431	0.00362	CcSEcCtD
Flunitrazepam—Ill-defined disorder—Mycophenolic acid—psoriasis	0.000427	0.00359	CcSEcCtD
Flunitrazepam—Agitation—Mycophenolic acid—psoriasis	0.000423	0.00355	CcSEcCtD
Flunitrazepam—Hallucination—Mycophenolate mofetil—psoriasis	0.000415	0.00349	CcSEcCtD
Flunitrazepam—Malaise—Mycophenolic acid—psoriasis	0.000415	0.00349	CcSEcCtD
Flunitrazepam—Muscular weakness—Betamethasone—psoriasis	0.000414	0.00348	CcSEcCtD
Flunitrazepam—Muscular weakness—Dexamethasone—psoriasis	0.000414	0.00348	CcSEcCtD
Flunitrazepam—Asthenia—Acitretin—psoriasis	0.00041	0.00344	CcSEcCtD
Flunitrazepam—Rash—Calcitriol—psoriasis	0.000405	0.0034	CcSEcCtD
Flunitrazepam—Dermatitis—Calcitriol—psoriasis	0.000405	0.0034	CcSEcCtD
Flunitrazepam—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000405	0.0124	CbGpPWpGaD
Flunitrazepam—UGT1A3—Biological oxidations—CYP2S1—psoriasis	0.000404	0.0123	CbGpPWpGaD
Flunitrazepam—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000403	0.0123	CbGpPWpGaD
Flunitrazepam—Headache—Calcitriol—psoriasis	0.000403	0.00338	CcSEcCtD
Flunitrazepam—Psychotic disorder—Prednisone—psoriasis	0.0004	0.00335	CcSEcCtD
Flunitrazepam—Somnolence—Hydroxyurea—psoriasis	0.000399	0.00335	CcSEcCtD
Flunitrazepam—UGT1A3—Metapathway biotransformation—CYP2S1—psoriasis	0.000398	0.0121	CbGpPWpGaD
Flunitrazepam—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000397	0.0121	CbGpPWpGaD
Flunitrazepam—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000395	0.012	CbGpPWpGaD
Flunitrazepam—Anxiety—Mycophenolic acid—psoriasis	0.000391	0.00328	CcSEcCtD
Flunitrazepam—Irritability—Prednisone—psoriasis	0.00039	0.00328	CcSEcCtD
Flunitrazepam—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000389	0.0119	CbGpPWpGaD
Flunitrazepam—Discomfort—Mycophenolic acid—psoriasis	0.000387	0.00325	CcSEcCtD
Flunitrazepam—Fatigue—Hydroxyurea—psoriasis	0.000387	0.00325	CcSEcCtD
Flunitrazepam—Dry mouth—Mycophenolic acid—psoriasis	0.000383	0.00322	CcSEcCtD
Flunitrazepam—Confusional state—Mycophenolic acid—psoriasis	0.000379	0.00318	CcSEcCtD
Flunitrazepam—Hallucination—Hydrocortisone—psoriasis	0.000378	0.00318	CcSEcCtD
Flunitrazepam—Dizziness—Acitretin—psoriasis	0.000378	0.00317	CcSEcCtD
Flunitrazepam—Dizziness—Fluocinolone Acetonide—psoriasis	0.000377	0.00316	CcSEcCtD
Flunitrazepam—Feeling abnormal—Hydroxyurea—psoriasis	0.00037	0.0031	CcSEcCtD
Flunitrazepam—Tachycardia—Mycophenolic acid—psoriasis	0.000367	0.00308	CcSEcCtD
Flunitrazepam—Hyperhidrosis—Mycophenolic acid—psoriasis	0.000363	0.00305	CcSEcCtD
Flunitrazepam—Muscular weakness—Prednisone—psoriasis	0.000361	0.00303	CcSEcCtD
Flunitrazepam—Rash—Acitretin—psoriasis	0.00036	0.00303	CcSEcCtD
Flunitrazepam—Dermatitis—Acitretin—psoriasis	0.00036	0.00302	CcSEcCtD
Flunitrazepam—Rash—Fluocinolone Acetonide—psoriasis	0.000359	0.00302	CcSEcCtD
Flunitrazepam—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000359	0.00301	CcSEcCtD
Flunitrazepam—Headache—Acitretin—psoriasis	0.000358	0.00301	CcSEcCtD
Flunitrazepam—Headache—Fluocinolone Acetonide—psoriasis	0.000357	0.003	CcSEcCtD
Flunitrazepam—Hypotension—Mycophenolic acid—psoriasis	0.000351	0.00295	CcSEcCtD
Flunitrazepam—Tremor—Cyclosporine—psoriasis	0.000349	0.00293	CcSEcCtD
Flunitrazepam—Ill-defined disorder—Cyclosporine—psoriasis	0.000346	0.0029	CcSEcCtD
Flunitrazepam—UGT2B7—Biological oxidations—CYP2S1—psoriasis	0.000343	0.0105	CbGpPWpGaD
Flunitrazepam—Agitation—Cyclosporine—psoriasis	0.000342	0.00287	CcSEcCtD
Flunitrazepam—Tremor—Mycophenolate mofetil—psoriasis	0.000341	0.00286	CcSEcCtD
Flunitrazepam—Angioedema—Cyclosporine—psoriasis	0.00034	0.00286	CcSEcCtD
Flunitrazepam—UGT2B7—Metapathway biotransformation—CYP2S1—psoriasis	0.000338	0.0103	CbGpPWpGaD
Flunitrazepam—Ill-defined disorder—Mycophenolate mofetil—psoriasis	0.000337	0.00283	CcSEcCtD
Flunitrazepam—Malaise—Cyclosporine—psoriasis	0.000336	0.00282	CcSEcCtD
Flunitrazepam—Somnolence—Mycophenolic acid—psoriasis	0.000334	0.0028	CcSEcCtD
Flunitrazepam—Agitation—Mycophenolate mofetil—psoriasis	0.000334	0.0028	CcSEcCtD
Flunitrazepam—Angioedema—Mycophenolate mofetil—psoriasis	0.000332	0.00279	CcSEcCtD
Flunitrazepam—Malaise—Mycophenolate mofetil—psoriasis	0.000328	0.00275	CcSEcCtD
Flunitrazepam—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000327	0.00997	CbGpPWpGaD
Flunitrazepam—Irritability—Methotrexate—psoriasis	0.000326	0.00274	CcSEcCtD
Flunitrazepam—Fatigue—Mycophenolic acid—psoriasis	0.000324	0.00272	CcSEcCtD
Flunitrazepam—Hallucination—Betamethasone—psoriasis	0.000323	0.00271	CcSEcCtD
Flunitrazepam—Hallucination—Dexamethasone—psoriasis	0.000323	0.00271	CcSEcCtD
Flunitrazepam—Asthenia—Hydroxyurea—psoriasis	0.000322	0.0027	CcSEcCtD
Flunitrazepam—Ataxia—Methotrexate—psoriasis	0.000321	0.0027	CcSEcCtD
Flunitrazepam—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00032	0.00976	CbGpPWpGaD
Flunitrazepam—Anxiety—Cyclosporine—psoriasis	0.000316	0.00265	CcSEcCtD
Flunitrazepam—Ill-defined disorder—Prednisolone—psoriasis	0.000315	0.00264	CcSEcCtD
Flunitrazepam—Discomfort—Cyclosporine—psoriasis	0.000313	0.00263	CcSEcCtD
Flunitrazepam—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000313	0.00954	CbGpPWpGaD
Flunitrazepam—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000311	0.00948	CbGpPWpGaD
Flunitrazepam—Dry mouth—Cyclosporine—psoriasis	0.00031	0.0026	CcSEcCtD
Flunitrazepam—Angioedema—Prednisolone—psoriasis	0.00031	0.0026	CcSEcCtD
Flunitrazepam—Feeling abnormal—Mycophenolic acid—psoriasis	0.00031	0.0026	CcSEcCtD
Flunitrazepam—Anxiety—Mycophenolate mofetil—psoriasis	0.000308	0.00259	CcSEcCtD
Flunitrazepam—Ill-defined disorder—Hydrocortisone—psoriasis	0.000307	0.00258	CcSEcCtD
Flunitrazepam—Confusional state—Cyclosporine—psoriasis	0.000307	0.00257	CcSEcCtD
Flunitrazepam—Malaise—Prednisolone—psoriasis	0.000306	0.00257	CcSEcCtD
Flunitrazepam—Discomfort—Mycophenolate mofetil—psoriasis	0.000306	0.00257	CcSEcCtD
Flunitrazepam—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000304	0.00929	CbGpPWpGaD
Flunitrazepam—Dry mouth—Mycophenolate mofetil—psoriasis	0.000303	0.00254	CcSEcCtD
Flunitrazepam—Angioedema—Hydrocortisone—psoriasis	0.000303	0.00254	CcSEcCtD
Flunitrazepam—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.0003	0.00917	CbGpPWpGaD
Flunitrazepam—Confusional state—Mycophenolate mofetil—psoriasis	0.000299	0.00251	CcSEcCtD
Flunitrazepam—Malaise—Hydrocortisone—psoriasis	0.000299	0.00251	CcSEcCtD
Flunitrazepam—Dizziness—Hydroxyurea—psoriasis	0.000297	0.00249	CcSEcCtD
Flunitrazepam—Hyperhidrosis—Cyclosporine—psoriasis	0.000294	0.00247	CcSEcCtD
Flunitrazepam—Tachycardia—Mycophenolate mofetil—psoriasis	0.00029	0.00243	CcSEcCtD
Flunitrazepam—Ill-defined disorder—Triamcinolone—psoriasis	0.000289	0.00243	CcSEcCtD
Flunitrazepam—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000287	0.00241	CcSEcCtD
Flunitrazepam—Discomfort—Prednisolone—psoriasis	0.000285	0.00239	CcSEcCtD
Flunitrazepam—Angioedema—Triamcinolone—psoriasis	0.000285	0.00239	CcSEcCtD
Flunitrazepam—Rash—Hydroxyurea—psoriasis	0.000283	0.00238	CcSEcCtD
Flunitrazepam—Dermatitis—Hydroxyurea—psoriasis	0.000283	0.00237	CcSEcCtD
Flunitrazepam—Hallucination—Prednisone—psoriasis	0.000282	0.00236	CcSEcCtD
Flunitrazepam—Malaise—Triamcinolone—psoriasis	0.000281	0.00236	CcSEcCtD
Flunitrazepam—Headache—Hydroxyurea—psoriasis	0.000281	0.00236	CcSEcCtD
Flunitrazepam—Anxiety—Hydrocortisone—psoriasis	0.000281	0.00236	CcSEcCtD
Flunitrazepam—UGT1A1—Biological oxidations—CYP2S1—psoriasis	0.000279	0.00851	CbGpPWpGaD
Flunitrazepam—Discomfort—Hydrocortisone—psoriasis	0.000279	0.00234	CcSEcCtD
Flunitrazepam—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000278	0.00847	CbGpPWpGaD
Flunitrazepam—Hypotension—Mycophenolate mofetil—psoriasis	0.000277	0.00233	CcSEcCtD
Flunitrazepam—UGT1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000275	0.00839	CbGpPWpGaD
Flunitrazepam—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000274	0.00836	CbGpPWpGaD
Flunitrazepam—Somnolence—Cyclosporine—psoriasis	0.00027	0.00227	CcSEcCtD
Flunitrazepam—Tachycardia—Prednisolone—psoriasis	0.00027	0.00227	CcSEcCtD
Flunitrazepam—Asthenia—Mycophenolic acid—psoriasis	0.00027	0.00226	CcSEcCtD
Flunitrazepam—Hyperhidrosis—Prednisolone—psoriasis	0.000267	0.00225	CcSEcCtD
Flunitrazepam—Tachycardia—Hydrocortisone—psoriasis	0.000264	0.00221	CcSEcCtD
Flunitrazepam—Somnolence—Mycophenolate mofetil—psoriasis	0.000264	0.00221	CcSEcCtD
Flunitrazepam—Drowsiness—Methotrexate—psoriasis	0.000263	0.00221	CcSEcCtD
Flunitrazepam—Ill-defined disorder—Betamethasone—psoriasis	0.000262	0.0022	CcSEcCtD
Flunitrazepam—Ill-defined disorder—Dexamethasone—psoriasis	0.000262	0.0022	CcSEcCtD
Flunitrazepam—Discomfort—Triamcinolone—psoriasis	0.000262	0.0022	CcSEcCtD
Flunitrazepam—Fatigue—Cyclosporine—psoriasis	0.000262	0.0022	CcSEcCtD
Flunitrazepam—Hyperhidrosis—Hydrocortisone—psoriasis	0.000261	0.00219	CcSEcCtD
Flunitrazepam—Dry mouth—Triamcinolone—psoriasis	0.00026	0.00218	CcSEcCtD
Flunitrazepam—Angioedema—Betamethasone—psoriasis	0.000258	0.00217	CcSEcCtD
Flunitrazepam—Angioedema—Dexamethasone—psoriasis	0.000258	0.00217	CcSEcCtD
Flunitrazepam—GABRA6—Orphan transporters—CARM1—psoriasis	0.000258	0.00788	CbGpPWpGaD
Flunitrazepam—Malaise—Dexamethasone—psoriasis	0.000255	0.00214	CcSEcCtD
Flunitrazepam—Malaise—Betamethasone—psoriasis	0.000255	0.00214	CcSEcCtD
Flunitrazepam—GABRA4—Orphan transporters—CARM1—psoriasis	0.000255	0.00778	CbGpPWpGaD
Flunitrazepam—Sweating—Methotrexate—psoriasis	0.000253	0.00212	CcSEcCtD
Flunitrazepam—Hypotension—Hydrocortisone—psoriasis	0.000253	0.00212	CcSEcCtD
Flunitrazepam—Feeling abnormal—Cyclosporine—psoriasis	0.000251	0.0021	CcSEcCtD
Flunitrazepam—Dizziness—Mycophenolic acid—psoriasis	0.000249	0.00209	CcSEcCtD
Flunitrazepam—Tachycardia—Triamcinolone—psoriasis	0.000248	0.00208	CcSEcCtD
Flunitrazepam—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000247	0.00753	CbGpPWpGaD
Flunitrazepam—Hyperhidrosis—Triamcinolone—psoriasis	0.000246	0.00206	CcSEcCtD
Flunitrazepam—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000244	0.00205	CcSEcCtD
Flunitrazepam—Anxiety—Betamethasone—psoriasis	0.00024	0.00201	CcSEcCtD
Flunitrazepam—Anxiety—Dexamethasone—psoriasis	0.00024	0.00201	CcSEcCtD
Flunitrazepam—Discomfort—Dexamethasone—psoriasis	0.000238	0.002	CcSEcCtD
Flunitrazepam—Discomfort—Betamethasone—psoriasis	0.000238	0.002	CcSEcCtD
Flunitrazepam—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000237	0.00724	CbGpPWpGaD
Flunitrazepam—Rash—Mycophenolic acid—psoriasis	0.000237	0.00199	CcSEcCtD
Flunitrazepam—Dermatitis—Mycophenolic acid—psoriasis	0.000237	0.00199	CcSEcCtD
Flunitrazepam—Headache—Mycophenolic acid—psoriasis	0.000235	0.00198	CcSEcCtD
Flunitrazepam—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000234	0.00714	CbGpPWpGaD
Flunitrazepam—Fatigue—Hydrocortisone—psoriasis	0.000233	0.00196	CcSEcCtD
Flunitrazepam—Ill-defined disorder—Prednisone—psoriasis	0.000229	0.00192	CcSEcCtD
Flunitrazepam—Feeling abnormal—Prednisolone—psoriasis	0.000228	0.00191	CcSEcCtD
Flunitrazepam—Agitation—Prednisone—psoriasis	0.000226	0.0019	CcSEcCtD
Flunitrazepam—GABRA5—Orphan transporters—CARM1—psoriasis	0.000226	0.00691	CbGpPWpGaD
Flunitrazepam—Tachycardia—Dexamethasone—psoriasis	0.000225	0.00189	CcSEcCtD
Flunitrazepam—Tachycardia—Betamethasone—psoriasis	0.000225	0.00189	CcSEcCtD
Flunitrazepam—Angioedema—Prednisone—psoriasis	0.000225	0.00189	CcSEcCtD
Flunitrazepam—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000225	0.00687	CbGpPWpGaD
Flunitrazepam—UGT1A3—NRF2 pathway—TGFA—psoriasis	0.000225	0.00686	CbGpPWpGaD
Flunitrazepam—Hyperhidrosis—Betamethasone—psoriasis	0.000223	0.00187	CcSEcCtD
Flunitrazepam—Hyperhidrosis—Dexamethasone—psoriasis	0.000223	0.00187	CcSEcCtD
Flunitrazepam—Feeling abnormal—Hydrocortisone—psoriasis	0.000223	0.00187	CcSEcCtD
Flunitrazepam—GABRA3—Orphan transporters—CARM1—psoriasis	0.000222	0.00678	CbGpPWpGaD
Flunitrazepam—Malaise—Prednisone—psoriasis	0.000222	0.00186	CcSEcCtD
Flunitrazepam—Fatigue—Triamcinolone—psoriasis	0.000219	0.00184	CcSEcCtD
Flunitrazepam—GABRA2—Orphan transporters—CARM1—psoriasis	0.000218	0.00667	CbGpPWpGaD
Flunitrazepam—Asthenia—Cyclosporine—psoriasis	0.000218	0.00183	CcSEcCtD
Flunitrazepam—Hypotension—Betamethasone—psoriasis	0.000216	0.00181	CcSEcCtD
Flunitrazepam—Hypotension—Dexamethasone—psoriasis	0.000216	0.00181	CcSEcCtD
Flunitrazepam—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000215	0.00656	CbGpPWpGaD
Flunitrazepam—Asthenia—Mycophenolate mofetil—psoriasis	0.000213	0.00179	CcSEcCtD
Flunitrazepam—Feeling abnormal—Triamcinolone—psoriasis	0.00021	0.00176	CcSEcCtD
Flunitrazepam—Anxiety—Prednisone—psoriasis	0.000209	0.00175	CcSEcCtD
Flunitrazepam—Discomfort—Prednisone—psoriasis	0.000207	0.00174	CcSEcCtD
Flunitrazepam—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000207	0.00632	CbGpPWpGaD
Flunitrazepam—Dizziness—Cyclosporine—psoriasis	0.000201	0.00169	CcSEcCtD
Flunitrazepam—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000199	0.00609	CbGpPWpGaD
Flunitrazepam—Fatigue—Betamethasone—psoriasis	0.000199	0.00167	CcSEcCtD
Flunitrazepam—Fatigue—Dexamethasone—psoriasis	0.000199	0.00167	CcSEcCtD
Flunitrazepam—Tachycardia—Prednisone—psoriasis	0.000196	0.00165	CcSEcCtD
Flunitrazepam—Dizziness—Mycophenolate mofetil—psoriasis	0.000196	0.00165	CcSEcCtD
Flunitrazepam—Hyperhidrosis—Prednisone—psoriasis	0.000194	0.00163	CcSEcCtD
Flunitrazepam—Asthenia—Hydrocortisone—psoriasis	0.000194	0.00163	CcSEcCtD
Flunitrazepam—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000193	0.0059	CbGpPWpGaD
Flunitrazepam—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000192	0.00587	CbGpPWpGaD
Flunitrazepam—Rash—Cyclosporine—psoriasis	0.000192	0.00161	CcSEcCtD
Flunitrazepam—Dermatitis—Cyclosporine—psoriasis	0.000192	0.00161	CcSEcCtD
Flunitrazepam—UGT2B7—NRF2 pathway—TGFA—psoriasis	0.000191	0.00583	CbGpPWpGaD
Flunitrazepam—Ill-defined disorder—Methotrexate—psoriasis	0.000191	0.0016	CcSEcCtD
Flunitrazepam—Headache—Cyclosporine—psoriasis	0.00019	0.0016	CcSEcCtD
Flunitrazepam—Feeling abnormal—Betamethasone—psoriasis	0.00019	0.0016	CcSEcCtD
Flunitrazepam—Feeling abnormal—Dexamethasone—psoriasis	0.00019	0.0016	CcSEcCtD
Flunitrazepam—Rash—Mycophenolate mofetil—psoriasis	0.000187	0.00157	CcSEcCtD
Flunitrazepam—Dermatitis—Mycophenolate mofetil—psoriasis	0.000187	0.00157	CcSEcCtD
Flunitrazepam—GABRA1—Orphan transporters—CARM1—psoriasis	0.000186	0.00569	CbGpPWpGaD
Flunitrazepam—Headache—Mycophenolate mofetil—psoriasis	0.000186	0.00156	CcSEcCtD
Flunitrazepam—Malaise—Methotrexate—psoriasis	0.000186	0.00156	CcSEcCtD
Flunitrazepam—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000185	0.00565	CbGpPWpGaD
Flunitrazepam—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000183	0.00559	CbGpPWpGaD
Flunitrazepam—Dizziness—Prednisolone—psoriasis	0.000183	0.00154	CcSEcCtD
Flunitrazepam—Asthenia—Triamcinolone—psoriasis	0.000183	0.00153	CcSEcCtD
Flunitrazepam—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000181	0.00553	CbGpPWpGaD
Flunitrazepam—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000181	0.00553	CbGpPWpGaD
Flunitrazepam—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000181	0.00551	CbGpPWpGaD
Flunitrazepam—Dizziness—Hydrocortisone—psoriasis	0.000179	0.0015	CcSEcCtD
Flunitrazepam—Rash—Prednisolone—psoriasis	0.000174	0.00146	CcSEcCtD
Flunitrazepam—Dermatitis—Prednisolone—psoriasis	0.000174	0.00146	CcSEcCtD
Flunitrazepam—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000173	0.00529	CbGpPWpGaD
Flunitrazepam—Fatigue—Prednisone—psoriasis	0.000173	0.00146	CcSEcCtD
Flunitrazepam—Headache—Prednisolone—psoriasis	0.000173	0.00145	CcSEcCtD
Flunitrazepam—Discomfort—Methotrexate—psoriasis	0.000173	0.00145	CcSEcCtD
Flunitrazepam—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000171	0.00522	CbGpPWpGaD
Flunitrazepam—Rash—Hydrocortisone—psoriasis	0.00017	0.00143	CcSEcCtD
Flunitrazepam—Dermatitis—Hydrocortisone—psoriasis	0.00017	0.00143	CcSEcCtD
Flunitrazepam—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.00017	0.00519	CbGpPWpGaD
Flunitrazepam—Confusional state—Methotrexate—psoriasis	0.000169	0.00142	CcSEcCtD
Flunitrazepam—Headache—Hydrocortisone—psoriasis	0.000169	0.00142	CcSEcCtD
Flunitrazepam—Dizziness—Triamcinolone—psoriasis	0.000168	0.00141	CcSEcCtD
Flunitrazepam—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.000168	0.00511	CbGpPWpGaD
Flunitrazepam—UGT1A3—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000167	0.0051	CbGpPWpGaD
Flunitrazepam—Feeling abnormal—Prednisone—psoriasis	0.000166	0.00139	CcSEcCtD
Flunitrazepam—Asthenia—Dexamethasone—psoriasis	0.000166	0.00139	CcSEcCtD
Flunitrazepam—Asthenia—Betamethasone—psoriasis	0.000166	0.00139	CcSEcCtD
Flunitrazepam—Hyperhidrosis—Methotrexate—psoriasis	0.000162	0.00136	CcSEcCtD
Flunitrazepam—Rash—Triamcinolone—psoriasis	0.00016	0.00135	CcSEcCtD
Flunitrazepam—Dermatitis—Triamcinolone—psoriasis	0.00016	0.00135	CcSEcCtD
Flunitrazepam—Headache—Triamcinolone—psoriasis	0.000159	0.00134	CcSEcCtD
Flunitrazepam—GABRA1—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000158	0.00483	CbGpPWpGaD
Flunitrazepam—Hypotension—Methotrexate—psoriasis	0.000157	0.00132	CcSEcCtD
Flunitrazepam—UGT1A1—NRF2 pathway—TGFA—psoriasis	0.000155	0.00474	CbGpPWpGaD
Flunitrazepam—Dizziness—Dexamethasone—psoriasis	0.000153	0.00128	CcSEcCtD
Flunitrazepam—Dizziness—Betamethasone—psoriasis	0.000153	0.00128	CcSEcCtD
Flunitrazepam—Somnolence—Methotrexate—psoriasis	0.000149	0.00125	CcSEcCtD
Flunitrazepam—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000148	0.00453	CbGpPWpGaD
Flunitrazepam—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.000147	0.00447	CbGpPWpGaD
Flunitrazepam—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000146	0.00447	CbGpPWpGaD
Flunitrazepam—Rash—Betamethasone—psoriasis	0.000146	0.00122	CcSEcCtD
Flunitrazepam—Rash—Dexamethasone—psoriasis	0.000146	0.00122	CcSEcCtD
Flunitrazepam—Dermatitis—Betamethasone—psoriasis	0.000145	0.00122	CcSEcCtD
Flunitrazepam—Dermatitis—Dexamethasone—psoriasis	0.000145	0.00122	CcSEcCtD
Flunitrazepam—Fatigue—Methotrexate—psoriasis	0.000145	0.00122	CcSEcCtD
Flunitrazepam—Headache—Betamethasone—psoriasis	0.000145	0.00121	CcSEcCtD
Flunitrazepam—Headache—Dexamethasone—psoriasis	0.000145	0.00121	CcSEcCtD
Flunitrazepam—Asthenia—Prednisone—psoriasis	0.000144	0.00121	CcSEcCtD
Flunitrazepam—Feeling abnormal—Methotrexate—psoriasis	0.000138	0.00116	CcSEcCtD
Flunitrazepam—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000134	0.00408	CbGpPWpGaD
Flunitrazepam—Dizziness—Prednisone—psoriasis	0.000133	0.00112	CcSEcCtD
Flunitrazepam—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000131	0.004	CbGpPWpGaD
Flunitrazepam—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000129	0.00395	CbGpPWpGaD
Flunitrazepam—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000129	0.00394	CbGpPWpGaD
Flunitrazepam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000127	0.00389	CbGpPWpGaD
Flunitrazepam—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000127	0.00388	CbGpPWpGaD
Flunitrazepam—Rash—Prednisone—psoriasis	0.000127	0.00106	CcSEcCtD
Flunitrazepam—Dermatitis—Prednisone—psoriasis	0.000127	0.00106	CcSEcCtD
Flunitrazepam—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000126	0.00386	CbGpPWpGaD
Flunitrazepam—Headache—Prednisone—psoriasis	0.000126	0.00106	CcSEcCtD
Flunitrazepam—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	0.000125	0.00382	CbGpPWpGaD
Flunitrazepam—GABRA1—SIDS Susceptibility Pathways—IL13—psoriasis	0.000125	0.00382	CbGpPWpGaD
Flunitrazepam—Asthenia—Methotrexate—psoriasis	0.000121	0.00101	CcSEcCtD
Flunitrazepam—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.00012	0.00365	CbGpPWpGaD
Flunitrazepam—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.00012	0.00365	CbGpPWpGaD
Flunitrazepam—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000118	0.0036	CbGpPWpGaD
Flunitrazepam—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000116	0.00355	CbGpPWpGaD
Flunitrazepam—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000115	0.00353	CbGpPWpGaD
Flunitrazepam—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000114	0.00347	CbGpPWpGaD
Flunitrazepam—Dizziness—Methotrexate—psoriasis	0.000111	0.000933	CcSEcCtD
Flunitrazepam—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000109	0.00332	CbGpPWpGaD
Flunitrazepam—Rash—Methotrexate—psoriasis	0.000106	0.000889	CcSEcCtD
Flunitrazepam—Dermatitis—Methotrexate—psoriasis	0.000106	0.000888	CcSEcCtD
Flunitrazepam—Headache—Methotrexate—psoriasis	0.000105	0.000884	CcSEcCtD
Flunitrazepam—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000102	0.00312	CbGpPWpGaD
Flunitrazepam—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000101	0.00307	CbGpPWpGaD
Flunitrazepam—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000101	0.00307	CbGpPWpGaD
Flunitrazepam—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	9.9e-05	0.00302	CbGpPWpGaD
Flunitrazepam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.89e-05	0.00271	CbGpPWpGaD
Flunitrazepam—CYP1A2—Tryptophan metabolism—CAT—psoriasis	8.81e-05	0.00269	CbGpPWpGaD
Flunitrazepam—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	8.65e-05	0.00264	CbGpPWpGaD
Flunitrazepam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.41e-05	0.00257	CbGpPWpGaD
Flunitrazepam—UGT1A3—Metabolism—NDUFA5—psoriasis	8.12e-05	0.00248	CbGpPWpGaD
Flunitrazepam—CYP3A4—Biological oxidations—CYP2S1—psoriasis	7.88e-05	0.00241	CbGpPWpGaD
Flunitrazepam—GABRA1—SIDS Susceptibility Pathways—IL10—psoriasis	7.82e-05	0.00239	CbGpPWpGaD
Flunitrazepam—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	7.77e-05	0.00237	CbGpPWpGaD
Flunitrazepam—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	7.67e-05	0.00234	CbGpPWpGaD
Flunitrazepam—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.59e-05	0.00232	CbGpPWpGaD
Flunitrazepam—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	7.56e-05	0.00231	CbGpPWpGaD
Flunitrazepam—UGT1A3—Metabolism—CYP2S1—psoriasis	6.9e-05	0.00211	CbGpPWpGaD
Flunitrazepam—UGT2B7—Metabolism—NDUFA5—psoriasis	6.9e-05	0.00211	CbGpPWpGaD
Flunitrazepam—CYP3A4—Tryptophan metabolism—CAT—psoriasis	6.8e-05	0.00208	CbGpPWpGaD
Flunitrazepam—GABRA6—Transmembrane transport of small molecules—CP—psoriasis	6.6e-05	0.00202	CbGpPWpGaD
Flunitrazepam—GABRA4—Transmembrane transport of small molecules—CP—psoriasis	6.52e-05	0.00199	CbGpPWpGaD
Flunitrazepam—GABRA6—Transmembrane transport of small molecules—CARM1—psoriasis	6.3e-05	0.00192	CbGpPWpGaD
Flunitrazepam—GABRA4—Transmembrane transport of small molecules—CARM1—psoriasis	6.22e-05	0.0019	CbGpPWpGaD
Flunitrazepam—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	5.89e-05	0.0018	CbGpPWpGaD
Flunitrazepam—UGT2B7—Metabolism—CYP2S1—psoriasis	5.87e-05	0.00179	CbGpPWpGaD
Flunitrazepam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.86e-05	0.00179	CbGpPWpGaD
Flunitrazepam—GABRA5—Transmembrane transport of small molecules—CP—psoriasis	5.79e-05	0.00177	CbGpPWpGaD
Flunitrazepam—GABRA3—Transmembrane transport of small molecules—CP—psoriasis	5.69e-05	0.00174	CbGpPWpGaD
Flunitrazepam—UGT1A1—Metabolism—NDUFA5—psoriasis	5.61e-05	0.00171	CbGpPWpGaD
Flunitrazepam—GABRA2—Transmembrane transport of small molecules—CP—psoriasis	5.59e-05	0.00171	CbGpPWpGaD
Flunitrazepam—GABRA5—Transmembrane transport of small molecules—CARM1—psoriasis	5.53e-05	0.00169	CbGpPWpGaD
Flunitrazepam—GABRA3—Transmembrane transport of small molecules—CARM1—psoriasis	5.43e-05	0.00166	CbGpPWpGaD
Flunitrazepam—GABRA2—Transmembrane transport of small molecules—CARM1—psoriasis	5.33e-05	0.00163	CbGpPWpGaD
Flunitrazepam—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.89e-05	0.00149	CbGpPWpGaD
Flunitrazepam—UGT1A1—Metabolism—CYP2S1—psoriasis	4.77e-05	0.00146	CbGpPWpGaD
Flunitrazepam—GABRA1—Transmembrane transport of small molecules—CP—psoriasis	4.77e-05	0.00146	CbGpPWpGaD
Flunitrazepam—GABRA1—Transmembrane transport of small molecules—CARM1—psoriasis	4.55e-05	0.00139	CbGpPWpGaD
Flunitrazepam—CYP2A6—Metabolism—NDUFA5—psoriasis	4.32e-05	0.00132	CbGpPWpGaD
Flunitrazepam—GABRA1—SIDS Susceptibility Pathways—CXCL8—psoriasis	4.28e-05	0.00131	CbGpPWpGaD
Flunitrazepam—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.23e-05	0.00129	CbGpPWpGaD
Flunitrazepam—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.07e-05	0.00124	CbGpPWpGaD
Flunitrazepam—GABRA1—SIDS Susceptibility Pathways—JUN—psoriasis	3.98e-05	0.00121	CbGpPWpGaD
Flunitrazepam—GABRA1—SIDS Susceptibility Pathways—NFKB1—psoriasis	3.83e-05	0.00117	CbGpPWpGaD
Flunitrazepam—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.69e-05	0.00113	CbGpPWpGaD
Flunitrazepam—CYP2A6—Metabolism—CYP2S1—psoriasis	3.68e-05	0.00112	CbGpPWpGaD
Flunitrazepam—CYP2B6—Metabolism—NDUFA5—psoriasis	3.49e-05	0.00106	CbGpPWpGaD
Flunitrazepam—GABRA1—SIDS Susceptibility Pathways—VEGFA—psoriasis	3.47e-05	0.00106	CbGpPWpGaD
Flunitrazepam—CYP2E1—Metabolism—NDUFA5—psoriasis	3.42e-05	0.00104	CbGpPWpGaD
Flunitrazepam—UGT1A3—Metabolism—CARM1—psoriasis	3.37e-05	0.00103	CbGpPWpGaD
Flunitrazepam—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.17e-05	0.000967	CbGpPWpGaD
Flunitrazepam—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.17e-05	0.000967	CbGpPWpGaD
Flunitrazepam—GABRA1—SIDS Susceptibility Pathways—TNF—psoriasis	2.98e-05	0.000909	CbGpPWpGaD
Flunitrazepam—CYP2B6—Metabolism—CYP2S1—psoriasis	2.97e-05	0.000905	CbGpPWpGaD
Flunitrazepam—CYP2E1—Metabolism—CYP2S1—psoriasis	2.91e-05	0.000887	CbGpPWpGaD
Flunitrazepam—UGT2B7—Metabolism—CARM1—psoriasis	2.87e-05	0.000875	CbGpPWpGaD
Flunitrazepam—CYP2C19—Metabolism—NDUFA5—psoriasis	2.64e-05	0.000805	CbGpPWpGaD
Flunitrazepam—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.46e-05	0.00075	CbGpPWpGaD
Flunitrazepam—CYP2C9—Metabolism—NDUFA5—psoriasis	2.4e-05	0.000734	CbGpPWpGaD
Flunitrazepam—GABRA1—SIDS Susceptibility Pathways—IL6—psoriasis	2.4e-05	0.000733	CbGpPWpGaD
Flunitrazepam—UGT1A1—Metabolism—CARM1—psoriasis	2.33e-05	0.000711	CbGpPWpGaD
Flunitrazepam—CYP2C19—Metabolism—CYP2S1—psoriasis	2.24e-05	0.000684	CbGpPWpGaD
Flunitrazepam—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.24e-05	0.000684	CbGpPWpGaD
Flunitrazepam—UGT1A3—Metabolism—CAT—psoriasis	2.07e-05	0.000633	CbGpPWpGaD
Flunitrazepam—CYP1A2—Metabolism—NDUFA5—psoriasis	2.05e-05	0.000627	CbGpPWpGaD
Flunitrazepam—CYP2C9—Metabolism—CYP2S1—psoriasis	2.04e-05	0.000624	CbGpPWpGaD
Flunitrazepam—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.92e-05	0.000585	CbGpPWpGaD
Flunitrazepam—CYP2A6—Metabolism—CARM1—psoriasis	1.8e-05	0.000548	CbGpPWpGaD
Flunitrazepam—UGT2B7—Metabolism—CAT—psoriasis	1.76e-05	0.000538	CbGpPWpGaD
Flunitrazepam—CYP1A2—Metabolism—CYP2S1—psoriasis	1.75e-05	0.000533	CbGpPWpGaD
Flunitrazepam—UGT1A3—Metabolism—APOE—psoriasis	1.61e-05	0.000492	CbGpPWpGaD
Flunitrazepam—CYP3A4—Metabolism—NDUFA5—psoriasis	1.59e-05	0.000484	CbGpPWpGaD
Flunitrazepam—CYP2B6—Metabolism—CARM1—psoriasis	1.45e-05	0.000442	CbGpPWpGaD
Flunitrazepam—UGT1A1—Metabolism—CAT—psoriasis	1.43e-05	0.000437	CbGpPWpGaD
Flunitrazepam—CYP2E1—Metabolism—CARM1—psoriasis	1.42e-05	0.000433	CbGpPWpGaD
Flunitrazepam—UGT1A3—Metabolism—PPARG—psoriasis	1.4e-05	0.000428	CbGpPWpGaD
Flunitrazepam—UGT2B7—Metabolism—APOE—psoriasis	1.37e-05	0.000418	CbGpPWpGaD
Flunitrazepam—CYP3A4—Metabolism—CYP2S1—psoriasis	1.35e-05	0.000411	CbGpPWpGaD
Flunitrazepam—UGT2B7—Metabolism—PPARG—psoriasis	1.19e-05	0.000364	CbGpPWpGaD
Flunitrazepam—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.17e-05	0.000359	CbGpPWpGaD
Flunitrazepam—UGT1A1—Metabolism—APOE—psoriasis	1.11e-05	0.00034	CbGpPWpGaD
Flunitrazepam—CYP2A6—Metabolism—CAT—psoriasis	1.1e-05	0.000337	CbGpPWpGaD
Flunitrazepam—CYP2C19—Metabolism—CARM1—psoriasis	1.09e-05	0.000334	CbGpPWpGaD
Flunitrazepam—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.07e-05	0.000327	CbGpPWpGaD
Flunitrazepam—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.02e-05	0.000312	CbGpPWpGaD
Flunitrazepam—CYP2C9—Metabolism—CARM1—psoriasis	9.98e-06	0.000305	CbGpPWpGaD
Flunitrazepam—UGT1A1—Metabolism—PPARG—psoriasis	9.69e-06	0.000296	CbGpPWpGaD
Flunitrazepam—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.33e-06	0.000285	CbGpPWpGaD
Flunitrazepam—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.15e-06	0.000279	CbGpPWpGaD
Flunitrazepam—CYP2B6—Metabolism—CAT—psoriasis	8.91e-06	0.000272	CbGpPWpGaD
Flunitrazepam—CYP2E1—Metabolism—CAT—psoriasis	8.73e-06	0.000266	CbGpPWpGaD
Flunitrazepam—CYP2A6—Metabolism—APOE—psoriasis	8.58e-06	0.000262	CbGpPWpGaD
Flunitrazepam—CYP1A2—Metabolism—CARM1—psoriasis	8.53e-06	0.00026	CbGpPWpGaD
Flunitrazepam—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.97e-06	0.000243	CbGpPWpGaD
Flunitrazepam—CYP2A6—Metabolism—PPARG—psoriasis	7.47e-06	0.000228	CbGpPWpGaD
Flunitrazepam—CYP2B6—Metabolism—APOE—psoriasis	6.92e-06	0.000211	CbGpPWpGaD
Flunitrazepam—CYP2E1—Metabolism—APOE—psoriasis	6.78e-06	0.000207	CbGpPWpGaD
Flunitrazepam—CYP2C19—Metabolism—CAT—psoriasis	6.73e-06	0.000205	CbGpPWpGaD
Flunitrazepam—CYP3A4—Metabolism—CARM1—psoriasis	6.58e-06	0.000201	CbGpPWpGaD
Flunitrazepam—CYP2C9—Metabolism—CAT—psoriasis	6.14e-06	0.000187	CbGpPWpGaD
Flunitrazepam—CYP2B6—Metabolism—PPARG—psoriasis	6.03e-06	0.000184	CbGpPWpGaD
Flunitrazepam—CYP2E1—Metabolism—PPARG—psoriasis	5.91e-06	0.00018	CbGpPWpGaD
Flunitrazepam—CYP1A2—Metabolism—CAT—psoriasis	5.25e-06	0.00016	CbGpPWpGaD
Flunitrazepam—CYP2C19—Metabolism—APOE—psoriasis	5.23e-06	0.00016	CbGpPWpGaD
Flunitrazepam—CYP2C9—Metabolism—APOE—psoriasis	4.77e-06	0.000146	CbGpPWpGaD
Flunitrazepam—CYP2C19—Metabolism—PPARG—psoriasis	4.56e-06	0.000139	CbGpPWpGaD
Flunitrazepam—CYP2C9—Metabolism—PPARG—psoriasis	4.15e-06	0.000127	CbGpPWpGaD
Flunitrazepam—CYP1A2—Metabolism—APOE—psoriasis	4.08e-06	0.000124	CbGpPWpGaD
Flunitrazepam—CYP3A4—Metabolism—CAT—psoriasis	4.05e-06	0.000124	CbGpPWpGaD
Flunitrazepam—CYP1A2—Metabolism—PPARG—psoriasis	3.55e-06	0.000108	CbGpPWpGaD
Flunitrazepam—CYP3A4—Metabolism—APOE—psoriasis	3.15e-06	9.6e-05	CbGpPWpGaD
Flunitrazepam—CYP3A4—Metabolism—PPARG—psoriasis	2.74e-06	8.36e-05	CbGpPWpGaD
